{"filing":{"accession_number":"0001628280-26-039005","cik":"0000010795","ticker":"BDX","company_name":"BECTON DICKINSON \u0026 CO","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"bdx-20260529.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/10795/000162828026039005/bdx-20260529.htm"},"events":[{"id":8234,"run_id":7225,"accession_number":"0001628280-26-039005","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"BD discloses resumption of ChloraPrep™ and PurPrep™ shipments after a voluntary hold in response to an FDA Warning Letter for the El Paso manufacturing facility. While the disclosure emphasizes acceptable testing results and no patient safety signals, the underlying regulatory action (FDA Warning Letter) and product shipment disruption are material to investors assessing operational and regulatory risk, even though the immediate disclosure is framed positively.","company_name":"BECTON DICKINSON \u0026 CO","ticker":"BDX","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":[{"id":2864,"accession_number":"0001628280-26-039005","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"BD discloses resumption of ChloraPrep™ and PurPrep™ shipments after a voluntary hold in response to an FDA Warning Letter for the El Paso manufacturing facility. While the disclosure emphasizes acceptable testing results and no patient safety signals, the underlying regulatory action (FDA Warning Letter) and product shipment disruption are material to investors assessing operational and regulatory risk, even though the immediate disclosure is framed positively.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:38:22.934534+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2864,"accession_number":"0001628280-26-039005","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"BD discloses resumption of ChloraPrep™ and PurPrep™ shipments after a voluntary hold in response to an FDA Warning Letter for the El Paso manufacturing facility. While the disclosure emphasizes acceptable testing results and no patient safety signals, the underlying regulatory action (FDA Warning Letter) and product shipment disruption are material to investors assessing operational and regulatory risk, even though the immediate disclosure is framed positively.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:38:22.934534+00:00","company_name":"BECTON DICKINSON \u0026 CO","ticker":"BDX","filing_date":"2026-05-29"}]}